Grace Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 13, 2025

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	December 31, 2024	March 31, 2024
(Expressed in thousands except share data)	$	$
Assets
Current assets:
Cash and cash equivalents	11,055	23,005
Receivables	301	722
Prepaid expenses	583	283
Total current assets	11,939	24,010
Equipment, net	19	24
Intangible assets	41,128	41,128
Goodwill	8,138	8,138
Total assets	61,224	73,300
Liabilities and Stockholders’ equity
Current liabilities:
Trade and other payables	1,971	1,684
Total current liabilities	1,971	1,684
Derivative warrant liabilities	3,781	4,359
Deferred tax liability	3,333	5,514
Total liabilities	9,085	11,557
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding	—	—
Common stock, $0.0001 par value per share; 100,000,000 authorized; 10,139,861 and 9,399,404 shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively	1	1
Additional paid-in capital	279,499	278,899
Accumulated other comprehensive loss	(6,038)	(6,038)
Accumulated deficit	(221,323)	(211,119)
Total stockholders' equity	52,139	61,743
Total liabilities and stockholders’ equity	61,224	73,300

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.